BlueWillow Biologics | NanoBio Awarded Up to $10 Million in NIH Funding to Develop a Pandemic Influenza Vaccine
Summary
ANN ARBOR, Mich., (October 29, 2013) – NanoBio Corporation today announced that the company has been awarded an initial contract worth $5.5 million from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to develop a nanoemulsion (NE) adjuvant for use with a pandemic influenza vaccine. The funding from NIAID will specifically support the research and development of NanoVax®-Panflu, which combines NanoBio’s proprietary NE adjuvant with a plant-based recombinant H5 pandemic influenza antigen. Mr. Peralta added, “With this contract support from NIAID, we will further our studies of the NE adjuvant and its important role in enhancing vaccines against challenging respiratory infections and sexually transmitted diseases. We look forward to moving our NanoVax-Panflu vaccine towards the clinic and on the path to commercialization.” NanoBio’s NanoStat® technology platform employs a novel oil-in-water nanoemulsion that can incorporate, deliver and adjuvant multiple antigen types. NanoBio® Corporation is a privately-held biopharmaceutical company focused on developing and commercializing vaccines and anti-infective treatments derived from its patented NanoStat® technology platform.